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Abstract
Background: High-grade osteosarcoma is an aggressive tumor most often developing in the long bones of
adolescents, with a second peak in the 5th decade of life. Better knowledge on cellular signaling in this tumor may
identify new possibilities for targeted treatment.
Methods: We performed gene set analysis on previously published genome-wide gene expression data of
osteosarcoma cell lines (n=19) and pretreatment biopsies (n=84). We characterized overexpression of the insulin-like
growth factor receptor (IGF1R) signaling pathways in human osteosarcoma as compared with osteoblasts and with the
hypothesized progenitor cells of osteosarcoma – mesenchymal stem cells. This pathway plays a key role in the growth
and development of bone. Since most profound differences in mRNA expression were found at and upstream of the
receptor of this pathway, we set out to inhibit IR/IGF1R using OSI-906, a dual inhibitor for IR/IGF1R, on four
osteosarcoma cell lines. Inhibitory effects of this drug were measured by Western blotting and cell proliferation assays.
Results: OSI-906 had a strong inhibitory effect on proliferation of 3 of 4 osteosarcoma cell lines, with IC50s below
100 nM at 72 hrs of treatment. Phosphorylation of IRS-1, a direct downstream target of IGF1R signaling, was inhibited
in the responsive osteosarcoma cell lines.
Conclusions: This study provides an in vitro rationale for using IR/IGF1R inhibitors in preclinical studies of osteosarcoma.
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Background
High-grade osteosarcoma is the most prevalent primary
malignant bone tumor. The disease occurs most fre-
quently in children and adolescents at the site where
proliferation is most active, ie the metaphysis adjacent to
the epiphyseal plate [1]. The 5-year overall survival of
osteosarcoma patients has raised from 10-20% to
about 60% after the introduction of preoperative
chemotherapy in the 1970s. However, about 45% of
all patients still die because of distant metastasis. No
additional treatments have been found that can in-
crease survival significantly, and administering higher
doses of preoperative chemotherapy does not result
in improved outcomes [2,3]. Better knowledge on
cellular signaling in high-grade osteosarcoma may
identify new possibilities for targeted treatment of this
highly aggressive tumor.
We have previously described the roles of bone develop-
mental pathways Wnt, TGFβ/BMP, and Hedgehog signal-
ing in osteosarcoma, but unfortunately so far could not
identify suitable targets for treatment [4,5]. In addition to
these signal transduction pathways, insulin-like growth
factor 1 receptor (IGF1R) signaling plays a key role in the
growth and development of bone. Aberrant signaling of
this pathway has been implicated in various cancer types,
among others sarcomas [6,7]. Key players of insulin-like
growth factor (IGF) signaling are the ligands IGF1, IGF2,
which are circulating polypeptides that can be expressed
in endocrine, paracrine, and autocrine manners, and the
tyrosine kinase receptor IGF1R, which forms homodimers,
or hybrid receptors with the insulin receptor (IR) [8].
IGF1R and IR/IGF1R hybrids are activated by both IGF1
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and −2, which trigger autophosphorylation of IGF1R and
subsequent downstream signal transduction. A second
IGF receptor, IGF2R, can bind IGF2, but does not confer
intracellular signaling, thereby diminishing the bioavail-
ability of IGF2 to IGF1R [9]. Autophosphorylation of IR/
IGF1R receptors recruits the signaling proteins insulin re-
ceptor substrate (IRS) and Src homology 2 domain
containing transforming protein (Shc) to the cell mem-
brane, which get phosphorylated and subsequently activate
the downstream PI3K/Akt and Ras/Raf/ERK signaling
pathways, both of which are known to be important in
cancer. These pathways ultimately act on several biological
processes, such as transcription, proliferation, growth, and
survival [9-11]. Interestingly, treatment targeted against
IGF1R signaling has shown to be effective in a subset of
Ewing sarcoma, another bone tumor that manifests at
young age [12].
The role of the IGF1R pathway in growth has been il-
lustrated in studies of knockout mice. It was shown that
IGF1 null mice are 40% smaller than littermates, while
IGF1R null mice are approximately 55% smaller [13]. In
dogs, the size of different breeds was demonstrated to be
dependent on IGF1 plasma levels [7]. Additionally, a
specific IGF1 SNP haplotype was described to be com-
mon in small breed dogs and nearly absent in giant
breeds [14]. Interestingly, large and giant dog breeds are
more prone to develop osteosarcoma [15], which in dogs
is biologically very similar to the human disease [16].
Two recent studies on human osteosarcoma suggest a
positive correlation between patient birth-weight and
height at diagnosis and the development of the disease
[17,18]. Involvement of some members of IGF1R signal-
ing in osteosarcoma has been described (as has been
reviewed in Kolb et al. [19]), but the activity of this path-
way remains to be determined.
We have analyzed genome-wide gene expression in
high-grade osteosarcoma cell lines and pretreatment bi-
opsies, and observed significantly altered activity of
genes involved in IGF1R signaling when compared to
profiles of mesenchymal stem cells and osteoblasts. Spe-
cifically, upstream inhibitors of IGF1R signaling were
found to be downregulated in osteosarcoma, and low ex-
pression of these genes correlated with worse event-free
survival. We inhibited IR/IGF1R signaling with the dual
IR/IGF1R inhibitor OSI-906. This showed inhibition of
phosphorylation of IRS-1 and of strong inhibition of
proliferation in 3/4 osteosarcoma cell lines. Interestingly,
the cell line which could not be inhibited with OSI-906,
143B, has a k-ras oncogenic transformation, which is a
component of the Ras/Raf/ERK pathway, one of down-
stream effectors of IGF1R signaling. These results
suggest that IR/IGF1R signaling may be an effective
targeted for treatment of high-grade osteosarcoma
patients.
Methods
Cell culture
The 19 high-grade osteosarcoma cell lines that were used
in this study were characterized and are described in
Ottaviano et al. [20]. The 12 mesenchymal stem cell and 3
osteoblast cultures were previously described [21]. MSCs
have been previously [22] characterized through FACS
analysis and have been tested for their ability to be com-
mitted under proper conditions towards adipogenesis,
chondrogenesis and osteogenesis as described in Bernardo
et al. [23]. Osteoblast cultures were derived from MSCs
which were treated to undergo osteogenic differentiation.
Cell line DNA was short tandem repeat profiled to con-
firm cell line identity with use of the Cell ID system of
Promega (Madison, WI). For Western blotting experi-
ments, cells were maintained in RPMI 1640 (Invitrogen,
Carlsbad, CA), supplemented with 10% fetal bovine serum
(F7524, Sigma-Aldrich, St. Louis, MO) and 1% glutamax
(Gibco 35050, Invitrogen, Carlsbad, CA).
Microarray experiments, preprocessing, and data analysis
For genome-wide gene expression analysis, we used
Illumina Human-6 v2.0 BeadChips. Microarray experi-
ments and data preprocessing are described in Kuijjer et
al. [21]. Previously deposited genome-wide gene expres-
sion data of mesenchymal stem cells (MSCs) and osteo-
blasts can be found in the Gene Expression Ombinus
(GEO accession number GSE28974 and GSE33382, re-
spectively). Data from osteosarcoma cell lines have been
published before [24], but since we normalized and
processed all raw data together, we deposited normalized
values in the Gene Expression Omnibus (GEO, accession
number GSE42351, superseries accession GSE42352).
Data from the 84 high-grade osteosarcoma pretreatment
biopsies have been previously published (GEO accession
number GSE33382) [21]. Ethical guidelines of the individ-
ual European partner institutions were followed and
samples and clinical data were handled in a coded
fashion and stored in the EuroBoNeT biobank. We
determined significant differential expression between
osteosarcoma cell lines (n=19) and mesenchymal stem
cells (n=12), and between osteosarcoma cell lines and os-
teoblasts (n=3) using Bioconductor [25] package LIMMA
[26] in statistical language R [27]. Probes with Benjamini
and Hochberg false discovery rate-adjusted P-values <0.05
were considered to be significant. Gene set analysis was
performed on KEGG pathways [28] (Release 63.0, July 1,
2012) using R-package globaltest [29]. For each analysis,
the top 15 significant KEGG pathways were returned. All
returned pathways had a Benjamini and Hochberg false-
discovery rate-corrected P-value <1∙10-5. To visualize dif-
ferential expression in the IGF1R pathway, we performed
Core analyses using Ingenuity Pathways Analysis (IPA,
Ingenuity Systems, www.ingenuity.com).
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Antibodies and reagents
Rabbit monoclonal and polyclonal antibodies against
IGF1R and IRS-1, respectively (both 1:1,000) were
obtained from Cell Signaling (Danvers, MA). Rabbit
polyclonal antibody against phospho-IRS-1 (Y612,
1:1,000) was purchased from Biosource, Invitrogen
(Carlsbad, CA). A mouse monoclonal antibody against
α-tubulin from Abcam (Cambridge, UK) was used as a
loading control (1:3,000). Secondary antibodies (both
1:10,000, BD Transduction Laboratories, Lexington, KY)
were horseradish peroxidase (HRP) conjugated poly-
clonal goat-anti-rabbit IgG for components of the IR/
IGF1R pathway, and HRP conjugated polyclonal goat-
anti-mouse for α-tubulin. OSI-906 was purchased from
Selleck Chemicals LLC (Houston, TX).
Western blotting
Osteosarcoma cell lines OHS, KPD, SAOS2, and 143B
were treated with 0.5% DMSO or with 1 μM OSI-906
for 3 hrs, and were subsequently lysed using Mammalian
Protein Extraction Reagent (Thermo Scientific 78503),
to which Halt Phosphatase and Protease Inhibitor Cock-
tails (Thermo Scientific 78420 and 78418, respectively)
were added according to the manufacturer’s protocol.
Concentrations of cell lysates were determined using the
BioRad DC Protein Assay Kit (Biorad, Hercules, CA).
Per sample, 20 μg of protein was loaded on SDS-PAGE
gels. Lysate of HepG2-A16 cells transfected with IR and
stimulated with insulin, containing 10 μg of protein, was
taken along as a positive control. Western blotting was
performed as described in Schrage et al. [30].
Proliferation assays
OSI-906 was diluted in DMSO and stored at −20°C. OHS,
SAOS2, KPD, and 143B cells were plated in 96 wells
plates, using 4,000, 2,000, 12,000, and 2,000 cells per well,
respectively. After 24 hrs, OSI-906 was added in triplicate
at different concentrations – 0 nM, 0.01 nM, 0.1 nM, 1
nM, 10 nM, 100 nM, 1 μM, and 10 μM. The inhibitor was
incubated for 72 hrs and 96 hrs, in different experiments.
The results shown are representative results from at least
three independent experiments. Cell proliferation reagent
WST-1 (Roche) was incubated for 2 hrs and subsequently
measured using a Wallac 1420 VICTOR2 (Perkin Elmer,
Waltham, MA). Data were analyzed in Graphpad Prism
5.0 (www.graphpad.com). Relative IC50s were calculated
using results from the different concentrations up to the
highest dose where toxicity was not yet present.
Results
Enrichment of IGF1R signaling in high-grade
osteosarcoma
Genome-wide gene expression data were of good quality
for all cell lines. LIMMA analysis resulted in 7,891
probes encoding for differentially expressed (DE) genes
between osteosarcoma cell lines and MSCs, and 2,222
probes encoding for DE genes between osteosarcoma cells
and osteoblasts. We tested the global expression patterns
of KEGG pathways using globaltest [29] and determined
the intersection of the pathways most significantly differ-
ent in osteosarcoma cell lines as compared with MSCs,
and of osteosarcoma cell lines as compared with osteo-
blasts. This approach resulted in five significantly affected
pathways – insulin signaling pathway, oocyte meiosis, ubi-
quitin mediated proteolysis, progesterone-mediated oocyte
maturation, and glycerophospholipid metabolism. Details
of the globaltest are shown in Table 1. IGF1R signaling is
involved in three out of the five detected KEGG path-
ways (insulin signaling pathway, oocyte meiosis, and
progesterone-mediated oocyte maturation). Interestingly,
a globaltest on mRNA expression of previously published
pretreatment biopsies [21] compared with normal bones
[31]) also returned insulin signaling as the most signifi-
cantly affected pathway (data not shown). Notably, there is
no specific IGF1R signaling pathway in the KEGG data-
base [28]. Because of the over-representation of IGF1R
signaling, and because of its known role in cancer, we de-
cided to study expression of members of this pathway in
detail.
Differentially expressed genes of the IGF1R pathway
To determine which genes have the most specific up- or
downregulation in osteosarcoma, we combined lists of
significantly differentially expressed genes of osteosar-
coma cell lines (n=19) and a previously published set of
osteosarcoma pretreatment biopsies (n=84, GEO acces-
sion GSE33382) in comparison with mesenchymal stem
cells (n=12) and osteoblasts (n=3) by four-way Venn
analysis of all significantly affected probes with the same
direction of fold change (upregulated or downregulated
in all four analyses) (Additional files 1 and 2). We identi-
fied IGFBP4 and GAS6 as the most downregulated genes
in osteosarcoma (average log fold changes of -4.43
and -4.29, respectively). IGFBP2 was also present in the
top 20 results from this four-way analysis (see Additional
file 1). In addition, IGFBP3 and −7 were significantly
downregulated, and IGF2BP3 was significantly upregu-
lated in three out of the four analyses. Both IGFBP4 and
GAS6 show high variability in expression in osteosar-
coma cell lines and biopsies (Figure 1A). Patients of
whom biopsies had very low expression of these genes
had poor event-free survival profiles (log-rank test for
trend, P = 0.01 for IGFBP4 and P = 0.04 for GAS6,
Figure 1B). To visualize mRNA expression of the IGF1R
signaling pathway members, we used Ingenuity Pathways
Analysis on LIMMA toptables from osteosarcoma cells
as compared with mesenchymal stem cells and from
osteosarcoma cells as compared with osteoblasts
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(Figure 2). As can be seen in this figure, overlap of dif-
ferentially expressed genes between these analyses was
detected upstream of IGF1R.
OSI-906 inhibits phosphorylation of IRS-1
Gene expression levels of IGF1R and IRS-1 were vali-
dated at the protein level by Western blot analysis
(Additional file 3). To determine the activity of IR/IGF1R
signaling, we performed Western blot analysis on cell
lysates of OHS, KPD, SAOS2, and 143B, using antibodies
against IRS-1 and phosphorylated IRS-1, before and after
treatment with OSI-906, a selective small molecule dual
kinase inhibitor of both IR and IGF1R, as IRS-1 is a direct
downstream target of IGF1R. An inhibition of intrinsic
IRS-1 phosphorylation at Y612 was detected after treat-
ment with OSI-906 in all cell lines (Figure 3), indicating
that this inhibitor could affect signaling downstream
IGF1R in osteosarcoma cells.
Table 1 Globaltest results
KEGG pathway Analysis adjP Statistic Expected Std.dev
Insulin signaling pathway OScellvsOB 1.01∙10-7 26.34 4.76 1.92
OScellvsMSC 3.07∙10-15 35.12 3.33 1.78
Oocyte meiosis OScellvsOB 2.70∙10-7 37.45 4.76 2.9
OScellvsMSC 5.04∙10-16 53.7 3.33 2.84
Ubiquitin mediated proteolysis OScellvsOB 3.21∙10-7 22.88 4.76 1.75
OScellvsMSC 5.04∙10-16 37.99 3.33 1.89
Progesterone-mediated oocyte maturation OScellvsOB 7.16∙10-7 34.26 4.76 2.71
OScellvsMSC 1.34∙10-15 55.35 3.33 2.77
Glycerophospholipid metabolism OScellvsOB 1.40∙10-6 27.13 4.76 2.25
OScellvsMSC 2.25∙10-15 55.86 3.33 2.82
The top five significant pathways with aberrant expression in both osteosarcoma cell lines versus osteoblasts (OScellvsOB) and osteosarcoma cell lines versus
mesenchymal stem cells (OScellvsMSC). adjP: FDR-adjusted p-value, Statistic: test statistic of the globaltest, Expected: expected test statistic of the globaltest, Std.
dev: standard deviation under the null hypothesis.
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Figure 1 mRNA expression of GAS6 and IGFBP4. A Normalized gene expression levels of GAS6 and IGFBP4 in osteosarcoma biopsies, cell lines,
mesenchymal stem cells (MSCs), and osteoblasts (OB). Expression of both proteins is considerably higher in the controls (FDR-adjusted P<0.001
for both genes in all four analyses). B Kaplan-Meier curves depicting metastasis-free survival in years for 83 high-grade osteosarcoma patients (for
1/84 patients, we did not have follow-up data available), based on quartiles of mRNA expression of the genes of interest.
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OSI-906 inhibits proliferation of 3 of 4 osteosarcoma cell
lines
In 3 of 4 osteosarcoma cell lines tested, inhibition with
OSI-906 was dose-dependent (Figure 4). Except for a toxic
response at the maximum dose of 10 μM (Additional
file 4), there was no effect on 143B. Because of this tox-
icity, relative IC50s were determined using measurements
until 1 μM. OHS, SAOS2, and KPD had an IC50 of 25 nM,
92 nM, and 90 nM at 72h, respectively, and of 37 nM, 57
nM, and 23 nM at 96h of inhibition, respectively. At 1 μM
OSI-906, approximately 60% of proliferation of OHS,
SAOS2, and KPD cells was inhibited, while 143B prolifera-
tion was not inhibited (Figure 4).
Discussion
Genome-wide gene expression and subsequent gene set
analysis on osteosarcoma cell lines and biopsies indi-
cated increased insulin-like growth factor signaling in
high-grade osteosarcoma as compared with the hypothe-
sized osteosarcoma progenitors, which is currently the
best control, since there is no benign precursor and no
certainty of the normal counterpart of osteosarcoma. Be-
cause IGF1R signaling can be exploited as a therapeutic
target, and osteosarcoma patients are in severe need of
new therapies, we examined mRNA expression of mem-
bers of this signaling pathway in detail. IGFBP4 and
GAS6, which code for proteins that inhibit IGF1R signal-
ing, showed the highest significant downregulation (log
fold changes <−4) in a four-way analysis, in which
IGFBP2 IGFBP6
IGFBP3 IGFBP5 IGFBP7
IGFBP4
IGFBP1
Figure 2 Ingenuity pathways analysis canonical pathway IGF1 signaling. This figure shows the IGF1 signaling pathway, with significantly
upregulated genes in red, downregulated genes in green, and genes that did not meet our criteria for significance in gray. The left part of the
symbols shows the analysis of osteosarcoma cell lines as compared with mesenchymal stem cells, the right part as compared with osteoblasts.
Most consensus in gene expression is found upstream IGF1R signaling, in the expression of the IGF binding proteins.
Figure 3 Validation of IR/IGF1R downstream signaling. Western
blot of IRS-1 and p-IRS-1 of lysates of untreated (−) osteosarcoma
cell lines OHS, KPD, SAOS2, and 143B, and of these cells treated for 3
hrs with 1 μM of OSI-906 (+).
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osteosarcoma pretreatment biopsies or cell lines were
compared with osteoblastic cultures (n=3) or MSCs
(n=12). Insulin-like growth factor binding proteins
(IGFBPs) generally inhibit IGF1R signaling by competi-
tively binding IGFs, but can under certain circumstances
also stimulate IGF1R signaling [32]. IGFBP4 is a negative
regulator of IGF signaling in various tissues, including
bone [33]. GAS6, or growth arrest-specific 6, was shown
to inhibit the growth promoting effects of IGF signaling
and to stimulate differentiation in the chondrogenic cell
line ATDC5 [34]. Both IGFBP4 and GAS6 expression
have previously been shown to be downregulated in
osteosarcoma cell lines (IGFBP4 in MG63 [35], GAS6 in
MG63 and SAOS2 cells [36]). Next to GAS6 and
IGFBP4, IGFBP2 was also significantly downregulated in
all four analyses, with log fold changes of approximately
-3. IGFBP2 generally inhibits IGF action and may play a
role in IGF2-induced osteoblast differentiation [33].
IGFBP3 was highly downregulated in three out of four
analyses, and has been shown to elicit anticancer effects
by inhibiting IGF1R signaling in Ewing sarcoma [37].
IGFBP7 activity has not yet been reported in sar-
coma, but has been associated with e.g. hepatocellular
carcinoma [38]. Interestingly, IGF2BP3 was highly
overexpressed in 3 of 4 analyses. This binding protein
can bind IGF2 mRNA, thereby probably activating the
translation of IGF2 [39]. Overexpression of IGF2BP3 has
been reported in several cancer types [40,41]. Figure 2
shows that differential expression is most pronounced in
upstream regulators of IGF1R, while downstream compo-
nents, such as SHC and FOS, are slightly downregulated,
although for most genes this only holds when compared
with mesenchymal stem cells, and not with osteoblasts.
This may be caused by negative feedback loops, triggered
by the active IGF1R signaling pathway. These results sug-
gest that, in osteosarcoma, the IGF1R signaling pathway
can be inhibited at the level of the receptor. We therefore
validated protein levels of IGF1R and of IRS-1, a direct
downstream component of IGF1R and IR signaling using
Western blotting. IGF1R and IRS-1 protein levels corre-
lated fairly well with mRNA expression levels. Most im-
portantly, phosphorylated IRS-1, which is a measure for
pathway activity, was detected in all four osteosarcoma cell
lines, indicating that IGF1R signaling is active in osteosar-
coma, and is possibly regulated upstream of IGF1R. Ac-
cordingly, targeting this receptor may be an effective way
to inhibit this pathway.
OSI-906 is a selective small molecule dual kinase in-
hibitor of both IR and IGF1R [42]. We specifically chose
to treat osteosarcoma cells with a dual inhibitor, because
the insulin receptor can activate the same downstream
signaling pathways as IGF1R, therefore providing cells a
way to circumvent single inhibition of IGF1R. This has
formerly been demonstrated in osteoblasts [43] and in
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Figure 4 Inhibition of osteosarcoma cell lines with OSI-906. Osteosarcoma cell lines were inhibited with different concentrations of OSI-906,
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Ewing sarcoma cells [44]. In fact, this dual inhibitor has
been shown to cause enhanced inhibition of the Akt sig-
naling pathway when compared with a selective monoclo-
nal antibody against IGF1R, which could inhibit IR/IGF1R
hybrids, but not IR homodimers [45]. OSI-906 is currently
being tested by OSI Pharmaceuticals in a Phase III trial in
adrenocortical carcinoma and in a Phase I/II clinical trial
in ovarian cancer. Treatment of osteosarcoma cells with
OSI-906 at physiological levels leads to decreased phos-
phorylation of IRS-1 at Y612. Inhibition of IRS-1 at Y612
after treatment with OSI-906 was previously reported by
Buck et al. in direct complementation breast cancer cells
for IGF1R-IGF2 and IR(A)-IGF2 [45]. Interestingly, we
also detected a small shift in the size of p-IRS-1 on the
Western Blot, indicating that multiple phosphorylation
groups are removed after treatment with OSI-906. Sur-
prisingly, total IRS-1 levels were highest in 143B, and were
downregulated after treatment with OSI-906 in this cell
line, although this had no effect on cell growth in this line,
as opposed to the three others, which showed low IC50s.
Proliferation of 143B was only inhibited most likely
unspecifically at high and toxic levels of the drug. The
143B cell line is a derivative of the osteosarcoma cell line
HOS, transformed by a KRAS oncogene. Constitutive acti-
vation of the Ras/Raf/ERK pathway can explain why pro-
liferation of this cell line cannot be inhibited by OSI-906.
Of the cell lines that were responsive to OSI-906, KPD
and OHS showed that treatment of 96 hrs was most ef-
fective, while SAOS2 already reached maximum inhibition
at 72 hrs.
IGF1R signaling has been previously modulated in sar-
coma in preclinical and clinical models. Several phase I
and II clinical trials including treatment with IGF1R mono-
clonal antibodies are currently being conducted in sar-
coma, especially in Ewing sarcoma (an overview of these
trials is given in Olmos et al. [46]). Monoclonal antibodies
against IGF1R have modest activity against Ewing sarcoma,
as was observed in a phase I/II study of figitumumab (par-
tial response in 14.2% of all subjects) [47] and in a phase II
study using R1507 (complete/partial response rate of 10%)
[48]. Results of a phase II study of ganitumab in subjects
with Ewing sarcoma and desmoplastic small round cell tu-
mors were published very recently, and reported clinical
benefit in 17% of all patients [49]. Preclinically, treatment
with different monoclonal antibodies against IGFR1 has
been performed in osteosarcoma xenograft models, in
which a response was detected in at least 60% of all cases
studied [50-52]. However, no objective responses were ob-
served in phase I trials testing monoclonal antibodies
[47,53,54], although 2 of 3 patients treated with R1507 had
prolonged stable disease [53]. Clinical data using dual
IGF1R/IR inhibitors osteosarcoma is still very limited [55].
Because resistance to highly specific IGF1R inhibitors may
develop through IR [44], blocking both IGF1R and IR with
a dual kinase inhibitor will most likely lead to better inhib-
ition of downstream IRS-1 signaling. We thus expect clin-
ical outcomes to improve for osteosarcoma patients
treated with dual IGF1R/IR inhibitor OSI-906. The effects
of combination of OSI-906 with chemotherapeutics in
osteosarcoma still need to be assessed before such a treat-
ment can be clinically tested.
Phosphorylated IRS could be used as a biomarker in
order to determine whether patients would respond to
IGF1R inhibition. Patients with tumors exhibiting an ac-
tivating mutation in downstream pathways will most
likely not respond to IGF1R inhibition. Further research
needs to be performed in order to assess these candidate
biomarkers for response to treatment. The IGF1R path-
way acts on several biological mechanisms that promote
tumor progression – mitogenesis, protection from apop-
tosis, malignant transformation, and metastasis [6]. It is
therefore possible that inhibiting these pathways with a
dual IR/IGF1R kinase inhibitor, such as OSI-906, may
reduce tumor sizes, as well as osteosarcoma metastasis,
the leading cause of death in these patients.
Conclusions
Using gene set analysis of genome-wide gene expression
data of high-grade osteosarcoma biopsies and cell lines,
we detected an over-representation of IGF1R signaling.
Specifically, different upstream inhibitors of IGF1R signal-
ing, eg several IGF binding proteins, were downregulated.
As this indicated the IGF1R receptor as a potential target
for treatment of osteosarcoma, we set out to inhibit this
receptor in four osteosarcoma cell lines. We used OSI-906,
a selective small molecule dual kinase inhibitor of both
IR and IGF1R, since the insulin receptor can activate the
same downstream signaling pathways as IGF1R, thereby
providing a way to circumvent single inhibition of IGF1R.
Treatment with OSI-906 resulted in inhibition of phos-
phorylation of IRS-1 Y612, a direct downstream target of
IGF1R, and in strong inhibition of proliferation in 3 of 4
osteosarcoma cell lines. The non-responsive cell line,
143B, has a k-ras oncogenic transformation, and may
therefore not respond to this treatment. In conclusion, we
have shown that IGF1R signaling is active in osteosar-
coma, and that dual inhibition of IR/IGF1R inhibits down-
stream signaling and proliferation of these cells.
Responsiveness to this treatment may be evaluated by
Western blotting against phosphorylated IRS. This study
provides an in vitro rationale for using dual IR/IGF1R in-
hibitors in preclinical studies of osteosarcoma.
Additional files
Additional file 1: Result from the four-way intersection of
differentially expressed probes with same direction of fold change
(all up- or all downregulated).
Kuijjer et al. BMC Cancer 2013, 13:245 Page 7 of 9
http://www.biomedcentral.com/1471-2407/13/245
Additional file 2: Four-way Venn diagram depicting A the number
of significantly differentially expressed probes in all four analyses B
the number of significantly differentially expression probes with
same direction of fold change in all four analyses (all up- or all
downregulated). In total, we detected 495 probes that were significant in
all analyses. 487/495 significant probes had the same direction of fold
change in all four analyses. CellvsOB: osteosarcoma cell lines vs osteoblasts,
CellvsMSC: osteosarcoma cell lines vs MSCs, BiopvsOB: osteosarcoma
biopsies vs osteoblasts, BiopvsMSC: osteosarcoma biopsies vs MSCs.
Additional file 3: Validation of expression levels or IGF1R and IRS-1.
A Normalized expression levels of IGF1R and IRS-1 in the panel of 19
osteosarcoma cell lines. For both genes, we selected cell lines with
relatively low and high mRNA expression (black dots), and determined
protein levels on cell lysates using Western blotting. B Western blotting
results of the selected cell lines.
Additional file 4: Dose response curves up to toxic levels of OSI-906.
Osteosarcoma cell lines were inhibited with different concentrations
of OSI-906, for 72 (gray line) or 96 (black line) hours.
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